Conferences - Results from #8800

EAU 2016 Informed decision-making for prostate-specific antigen screening - Session Highlights March 12, 2016

EAU 2016 The impact of 2012 United States Preventive Services Task Force (USPSTF) panel update on PSA screening practice: A nationwide, and state-by-state level analysis - Session Highlights March 12, 2016

EAU 2016 Differences in prostate specific antigen testing among urologists and primary care providers in the United States following the 2011 USPSTF recommendations - Session Highlights March 12, 2016

EAU 2016 Correlation between stage shift and differences in mortality between the two study arms of the ERSPC - Session Highlights March 12, 2016

EAU 2016 18-year follow up of the Gothenburg randomized population-based prostate cancer screening trial - Session Highlights March 12, 2016

EAU 2016 Interleukin-22 (IL-22), a T-cell secreted cytokine, contributes to renal cell carcinoma (RCC) progression and is associated with poor outcome in RCC patients - Session Highlights March 12, 2016

ASCO GU 2016 CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma - Session Highlights January 25, 2016

ASCO GU 2016 Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma - Session Highlights January 25, 2016

ASCO GU 2016 Bladder and Bowel Symptoms with Intensity-Modulated Radiation Therapy (IMRT) for Prostate Cancer - Poster January 20, 2016

ASCO GU 2016 What does the clinician need to know about the molecular genetics of testicular germ cell tumor? - Session Highlights January 19, 2016

ASCO GU 2016 Standards in First-line Chemotherapy for High-Risk GCT: Does this Include Dose Intensification? - Session Highlights January 19, 2016

ASCO GU 2016 More CNS Events With Enzalutamide Vs. Bicalutamide Treatment of mCRPC - Session Highlights January 18, 2016

ASCO GU 2016 Large Study Reveals Significant Glucocorticoid Use in Both Treated and Untreated Prostate Cancer Patients - Session Highlights (Updated) January 18, 2016

ASCO GU 2016 Among Treated Men with mCRPC, Researchers Find More Gaps in Refills with Enzalutamide Than Abiraterone - Session Highlights (Updated) January 18, 2016

ASCO GU 2016 Very early PSA response to abiraterone in mCRPC patients: A novel prognostic factor to predict overall survival. - Poster Session Highlights January 18, 2016

ASCO GU 2016 Management of metastatic prostate cancer patients in first line: Audit of real-life practices. - Session Highlights January 18, 2016

ASCO GU 2016 Clinicians’ attitudes and preferences in choosing the first line drug for mCRPC: Preliminary results from a multicenter Italian study after the introduction of abiraterone acetate (AA) January 18, 2016

In 2016, What is Progress in the Treatment of Hormone-Naïve Prostate Cancer? January 15, 2016

ASCO GU 2016 Cardiovascular events in prostate cancer patients: A comparative analysis of German claims data. - Session Highlights January 13, 2016

ASCO GU 2016 Evaluating abiraterone responses in African Americans with metastatic CRPC. - Session Highlights January 13, 2016

Page 441 of 522